on ABIVAX (EPA:ABVX)
Abivax: Results of the 2026 Annual General Meeting
On May 11, 2026, Abivax, a biotechnology company specializing in therapeutic treatments, held its Annual General Meeting. Chaired by Sylvie Grégoire, Chair of the Board of Directors, the meeting resulted in the adoption of all resolutions proposed by the Board. This included the approval of the financial statements for the 2025 fiscal year and the executive compensation policy. Delegations of authority for financial transactions were also granted to the Board. Details of the votes are available on the Abivax website.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news